External validation was performed by separately hierarchically clustering 934 patients with STEMI in an independent cohort[1] into 2 groups (232 and 702 individuals) based on Illumina HT12v4-profiled PBMC expression (median time 21 hour between cardiac catheterization and blood sampling). Probes with most variable expression intensities (SD≥0.5, 216 probes, excluding ribosomal genes) were used. From the 20 most differentially expressed genes in the discovery cohort described in the manuscript Toma et al. 2022 [2], 19 were available in the validation cohort. Column names include the Illumina identifyer and the mapped gene name as used in the discovery cohort. Values are log2-transformed, quantile-normalized, batch-corrected values, see also [1] for methodological details. Acknowledgement: This work is supported by LIFE – Leipzig Research Center for Civilization Diseases, Universität Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by means of the Free State of Saxony within the framework of the excellence initiative. 1) Teren A, Kirsten H, Beutner F, Scholz M, Holdt LM, Teupser D, Gutberlet M, Thiery J, Schuler G, Eitel I. Alteration of multiple leukocyte gene expression networks is linked with magnetic resonance markers of prognosis after acute st-elevation myocardial infarction. Scientific Reports. 2017;7:41705 2) Toma A, dos Santos C, Burzyńska B, Góra M, Kiliszek M, Stickle N, Kirsten H, Kosyakovsky L, Wang B, van Diepen S, Epelman S, Szekely Y, Marshall JC, Billia F, Lawler PR (2022), Diversity in the Expressed Genomic Host Response to Myocardial Infarction, submitted.